Xiqiao Zhou

1.9k total citations
66 papers, 1.3k citations indexed

About

Xiqiao Zhou is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Xiqiao Zhou has authored 66 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Epidemiology, 20 papers in Endocrinology, Diabetes and Metabolism and 18 papers in Molecular Biology. Recurrent topics in Xiqiao Zhou's work include Liver Disease Diagnosis and Treatment (19 papers), Diet, Metabolism, and Disease (8 papers) and Sphingolipid Metabolism and Signaling (6 papers). Xiqiao Zhou is often cited by papers focused on Liver Disease Diagnosis and Treatment (19 papers), Diet, Metabolism, and Disease (8 papers) and Sphingolipid Metabolism and Signaling (6 papers). Xiqiao Zhou collaborates with scholars based in China, United States and Macao. Xiqiao Zhou's co-authors include Xiaoning Zeng, Xiu‐Lan Sun, Huiping Zhou, Hui Kong, Phillip B. Hylemon, Ruihua Shi, William M. Pandak, Luyong Zhang, Renping Zhao and Qibiao Wu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Xiqiao Zhou

55 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiqiao Zhou China 18 479 342 299 248 165 66 1.3k
Gabriel Frampton United States 24 568 1.2× 393 1.1× 495 1.7× 404 1.6× 160 1.0× 52 1.7k
Matthew McMillin United States 22 497 1.0× 410 1.2× 496 1.7× 338 1.4× 63 0.4× 57 1.6k
Xuemei Zhang China 26 733 1.5× 185 0.5× 137 0.5× 211 0.9× 115 0.7× 76 1.9k
Andrew M. Miller United States 19 286 0.6× 423 1.2× 126 0.4× 76 0.3× 77 0.5× 26 1.7k
Lin Xu China 21 443 0.9× 391 1.1× 59 0.2× 228 0.9× 75 0.5× 104 1.4k
Shigeru Motomura Japan 26 731 1.5× 228 0.7× 76 0.3× 381 1.5× 93 0.6× 116 2.2k

Countries citing papers authored by Xiqiao Zhou

Since Specialization
Citations

This map shows the geographic impact of Xiqiao Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiqiao Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiqiao Zhou more than expected).

Fields of papers citing papers by Xiqiao Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiqiao Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiqiao Zhou. The network helps show where Xiqiao Zhou may publish in the future.

Co-authorship network of co-authors of Xiqiao Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Xiqiao Zhou. A scholar is included among the top collaborators of Xiqiao Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiqiao Zhou. Xiqiao Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
She, Yun, et al.. (2025). Associations of Systemic Immune-Inflammation Index With Mortality Risk Among Adults in Diabetic Kidney Disease, NHANES 1999 to 2018. Canadian Journal of Diabetes. 49(3). 152–163.e1. 2 indexed citations
2.
3.
Song, Siyuan, et al.. (2025). Nephroprotective Effects of Formononetin in Diabetic Kidney Disease: Mechanistic Insights and Therapeutic Potential. The American Journal of Chinese Medicine. 53(7). 2277–2305. 1 indexed citations
4.
5.
Wang, Xiaoxiao, Gaoxiang Wang, Yujuan Zhang, et al.. (2025). Xietu Hemu Prescription Improves Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Cohort Study. Journal of Multidisciplinary Healthcare. Volume 18. 4377–4389.
6.
7.
Zhou, Xiqiao, et al.. (2024). Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease. Lipids in Health and Disease. 23(1). 50–50. 4 indexed citations
8.
Tian, Jie, et al.. (2024). Institutional Nomogram for Estimating Risk of Metabolic Associated Fatty Liver Disease (MAFLD). Diabetes Metabolic Syndrome and Obesity. Volume 17. 3735–3752. 1 indexed citations
9.
Wang, Yanyan, et al.. (2024). Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases. SHILAP Revista de lepidopterología. 4(4). 262–283. 17 indexed citations
10.
Tian, Jie, et al.. (2024). The potential of insulin resistance indices to predict non-alcoholic fatty liver disease in patients with type 2 diabetes. BMC Endocrine Disorders. 24(1). 261–261. 3 indexed citations
11.
Wang, Yanyan, Derrick Zhao, Lianyong Su, et al.. (2024). Therapeutic potential of berberine in attenuating cholestatic liver injury: insights from a PSC mouse model. Cell & Bioscience. 14(1). 14–14. 5 indexed citations
12.
Zhang, Wenhui, et al.. (2024). Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies. Frontiers in Endocrinology. 15. 1484815–1484815. 2 indexed citations
13.
Zhang, Yujuan, et al.. (2024). The metabolic profiles and body composition of non-obese metabolic associated fatty liver disease. Frontiers in Endocrinology. 15. 1322563–1322563. 6 indexed citations
14.
Zhang, Ziqi, et al.. (2023). GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Frontiers in Endocrinology. 14. 1149328–1149328. 25 indexed citations
15.
Zhang, Ziqi, Qiling Zhang, Ying Kiat Tan, et al.. (2023). Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Frontiers in Endocrinology. 14. 1270115–1270115. 1 indexed citations
16.
Zhang, Shu, et al.. (2022). Duodenal Mucosa: A New Target for the Treatment of Type 2 Diabetes. Endocrine Practice. 29(1). 53–59. 6 indexed citations
17.
Wang, Yanyan, Xiqiao Zhou, Derrick Zhao, et al.. (2020). Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes. PLoS ONE. 15(5). e0232630–e0232630. 78 indexed citations
18.
Wang, Jian, Tongshan Wang, Jun Xu, et al.. (2016). Prognostic significance of X-ray cross-complementing gene 1 expression in gastric cancer. Chinese Journal of Cancer Research. 28(3). 355–361. 6 indexed citations
19.
Zhou, Xiqiao, Ruihua Shi, Elaine Studer, et al.. (2011). Berberine prevents free fatty acid-induced lipid accumulation by activating ERK through sphingosine-1-phosphate receptor 2 in hepatocytes. The FASEB Journal. 25. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabriel Frampton Breakdown of academic impact, for papers by Matthew McMillin Breakdown of academic impact, for papers by Xuemei Zhang Breakdown of academic impact, for papers by Andrew M. Miller Breakdown of academic impact, for papers by Lin Xu Breakdown of academic impact, for papers by Shigeru Motomura
Rankless by CCL
2026